Email this article CLINICAL EXPERIENCE WITH IMMUNOGLOBULIN SIGARDIS AS REPLACEMENT THERAPY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY
- Authors: Drobyshevskaya V.G.1,2, Krivtsun O.A.2
-
Affiliations:
- St. Petersburg Pasteur Research Institute of Epidemiology and Microbiology
- First St. Petersburg State I. Pavlov Medical University
- Issue: Vol 22, No 4 (2019)
- Pages: 1460-1462
- Section: ORIGINAL ARTICLES
- Submitted: 20.10.2020
- Accepted: 20.10.2020
- Published: 20.12.2019
- URL: https://rusimmun.ru/jour/article/view/551
- DOI: https://doi.org/10.31857/S102872210007057-7
- ID: 551
Cite item
Full Text
Abstract
Practically valuable information on the use of the IMMUNOGLOBULIN SIGARDIS drug as a pathogenetic treatment of patients with a defect in antibody production. The article presents data from the study of the drug for compliance with the criteria, presented to the Intravenous immunoglobulin by the World Health Organization, the comparative characteristics of the antibodies that make up the drug according to the spectra and titers with the Russian, the data on the clinical and laboratory efficacy of the drug.
About the authors
V. G. Drobyshevskaya
St. Petersburg Pasteur Research Institute of Epidemiology and Microbiology;First St. Petersburg State I. Pavlov Medical University
Author for correspondence.
Email: v.g.drobyshevskaia@yandex.ru
аllergist-immunologist, Medical Center;
high school teacher, Department of Immunology,
St. Petersburg
Russian FederationO. A. Krivtsun
First St. Petersburg State I. Pavlov Medical University
Email: fake@neicon.ru
student,
St. Petersburg
Russian FederationReferences
- Латышева Е. А. «Первичные иммунодефициты у взрослых. Особенности диагностики и лечения.», Москва, 2018 г.
- Федеральные клинические рекомендации по диагностике и лечению больных первичными иммунодефицитами с нарушением гуморального звена. РААКИ, Москва 2014 год.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).